Yair Einhorn @RealSimple1Arel

Here is a full-page ad that $HIMS has published in today’s edition of the New York Times. Call me naive & uneducated but how is it possible that HIMS & HERS is building its entire business model relying on other companies’ IP of their Obesity drugs - mainly $NVO & $LLY. $XBI

Innovation & entrepreneurship have always been the backbone of America’s success story. It’s great to see the current FDA’s "Make American Biotech Accelerate" (MABA) policy - under the leadership of FDA commissioner @DrMakaryFDA, supporting BioTech companies & entrepreneurs! $XBI

Dr. Marty Makary @DrMakaryFDA

a month ago

Innovation & entrepreneurship have always been the backbone of America’s success story. It’s great to see the current FDA’s "Make American Biotech Accelerate" (MABA) policy - under the leadership of FDA commissioner @DrMakaryFDA, supporting BioTech companies & entrepreneurs! $XBI https://t.co/J52N7wF5Tn

87 21 229 49K 5

WOW! 🚨🚨According to a recent Endpoint’s @maxonwifi 👇 - Vinay Prasad is back at the FDA resuming his previous role as the head of CBER at the agency. It took less than two weeks since Prasad walked away with a resounding resignation and now it would be interesting to see who it…

Yair Einhorn @yaireinhorn

a month ago

WOW! 🚨🚨According to a recent Endpoint’s @maxonwifi 👇 - Vinay Prasad is back at the FDA resuming his previous role as the head of CBER at the agency. It took less than two weeks since Prasad walked away with a resounding resignation and now it would be interesting to see who it… https://t.co/0oOXT0hya3

10 12 75 65K 6

I have started to look into the most clinical advanced CRISPR Gene Editing company and the only one who currently has an approved drug - @CRISPRTX. $CRSP Q2 financial report is already on my desk and as always - I promise to share with you anything interesting I may find. $XBI

Since many asked me - I divide each paragraph & mark it according to the following rationale: Pink - main topic (mainly headlines) Orange - Subtopic (mostly derives from the pink headline) Green - Key terms mentioned (Genes, Programs etc.) Blue - dates / % / financials $XBI

It feels to me as if 𝕏’s new Algo changes had a huge negative impact on the reach of scientific content & BioTech related posts as you can all see in my analytics screenshot👇I was wondering whether others who write about BioTech & science feel the same - or is it just me… $XBI

$SANA has just announced that it has commenced an underwritten public offering of $75M of shares of its common stock & of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, $SANA intends to grant the underwriters a 30-day…

1/🚨WOW! @CRISPRTX announced a new strategic partnership with Sirius Therapeutics to co-develop and co-commercialize SRSD107 - Sirius’ long-acting Factor XI (FXI) small interfering RNA (siRNA) candidate for the treatment of thromboembolic disorders. $CRSP will pay Sirius an…

@CRISPRTX @CrisprSam $CRSP just reported in its Q2 ER that In July, the European Medicines Agency - @EMA_News had authorized the initiation of a Phase 2 clinical trial of SRSD107 for thromboembolic disorders. The study is designed to evaluate the safety and efficacy of SRSD107 in preventing…

🚨@CRISPRTX announced in its Q2 ER that In July, the European Medicines Agency - @EMA_News had authorized the initiation of a Phase 2 clinical trial of SRSD107 for thromboembolic disorders. In may $CRSP singed a new strategic partnership with Sirius Therapeutics 🧵👇 to…

Yair Einhorn @yaireinhorn

4 months ago

🚨@CRISPRTX announced in its Q2 ER that In July, the European Medicines Agency - @EMA_News had authorized the initiation of a Phase 2 clinical trial of SRSD107 for thromboembolic disorders. In may $CRSP singed a new strategic partnership with Sirius Therapeutics 🧵👇 to… https://t.co/hbkkLLZf6C

11 12 52 20K 17

Download Image

According to the WSJ 🧵👇- U.S. & European BioTech companies have raised $11.2B in venture capital during the first half of 2025. That is much lower than the 2024 pace when BioTech companies successfully raised $28.6B. If the current pace continues, 2025 will be the slowest for…

Yair Einhorn @yaireinhorn

a month ago

According to the WSJ 🧵👇- U.S. & European BioTech companies have raised $11.2B in venture capital during the first half of 2025. That is much lower than the 2024 pace when BioTech companies successfully raised $28.6B. If the current pace continues, 2025 will be the slowest for… https://t.co/uXOoEAimUl

10 26 95 29K 59

Download Image

1/🚨 In @VertexPharma’s Q2 earnings report it is stated that CASGEVY - $VRTX & $CRSP first ever approved CRISPR Gene Editing therapy for treating Sickle Cell disease has generated $30.4M (!) in revenue during Q2 with 16 patients that were infused with CASGEVY. Promising! $XBI

@CRISPRTX @VertexPharma 6/Vertex has completed enrollment of children 5 to 11 years of age with SCD or TDT in two global Phase 3 studies of CASGEVY and is on track to complete dosing in the second half of 2025. $VRTX & $CRSP also continue to advance preclinical assets for gentler conditioning for…

1/According to this excellent WSJ article VCs are apparently stepping away from the BioTech sector! It seems that the relentless market uncertainty as well as narrowing opportunities to take BioTech startups public have led venture capitalists to take a step back from the BioTech…

I want to thank each one of my many friends on 𝕏 who wrote to me and to tell you how grateful I am for your friendship! This really means the world to me! ❤️🙏 And here is a great picture of my beloved grandmother Bella holding in her hands a little guy that you all know…😉❤️

Here is an excellent list of all (!) the upcoming earnings reports in the BioTech sector which are due next week - divided by their Ticker, Market cap & commercial stage. Kudos to @BiopharmIQ for a great 🧵, for being a unique source of knowledge for BioTech & a MUST follow! $XBI

BiopharmIQ by Amp @BiopharmIQ

a month ago

Here is an excellent list of all (!) the upcoming earnings reports in the BioTech sector which are due next week - divided by their Ticker, Market cap & commercial stage. Kudos to @BiopharmIQ for a great 🧵, for being a unique source of knowledge for BioTech & a MUST follow! $XBI

4 2 14 8K 11

Download Image

I have just received another payment 🎉 from 𝕏’s creator revenue program - and it is one of my biggest one yet! As always I’m grateful for being paid to do something which I love doing so much and I promise to give back every penny earned to the community by gifting premium…

$PRME has just announced the closing of its underwritten public offering of 43,700,000 shares of its common stock🧵👇, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per…

Yair Einhorn @yaireinhorn

a month ago

$PRME has just announced the closing of its underwritten public offering of 43,700,000 shares of its common stock🧵👇, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per… https://t.co/iV9M1s4gCW

5 7 44 28K 7

Download Image

The gross proceeds to $PRME from the offering are expected to be ~ $125.4M, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock in the offering are to be sold by @PrimeMedicine. This is a very important step in…

This is the cover of a six-page long story about $HIMS - published in the recent edition of Bloomberg, which in my opinion further demonstrates how big and colossal the failure of $NVO leadership truly is! How can $NVO allow Hims and Hers to be considered as a “GLP-1 company”…